Deoxyribonucleic Acid Trip
By Gina Maranto,
New York Times
| 08. 28. 2002
Book review of Gregory Stock,
Redesigning Humans: Our Inevitable
Genetic Future.
GREGORY STOCK has written an enthusiastic book in support of
germ-line manipulations -- that is, making genetic modifications
to eggs, sperm and embryos that can be passed on to future generations.
Like previous explorations of the subject by the ethicist Joseph
F. Fletcher, the lawyer John Robertson and the biologist James
Watson, among others, ''Redesigning Humans: Our Inevitable Genetic
Future'' serves as an apologia for those scientists and physicians
who are already edging toward such work in a piecemeal fashion
in research labs and in vitro fertilization clinics around the
world. It advocates the wholesale adoption of genetic manipulations
with the purpose of finally taking control of human evolution.
This, the author writes, ''is the ultimate expression and realization
of our humanity.''
Because of the breadth of his scientific knowledge and his
considerable flair as a writer, Stock -- who heads the program
on medicine, technology and society at the School of Medicine
of the University of California, Los Angeles -- is a forceful
advocate. First and foremost...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...